株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

馬脳炎:パイプライン製品の分析

Equine Encephalitis - Pipeline Review, H2 2016

発行 Global Markets Direct 商品コード 229777
出版日 ページ情報 英文 51 Pages
即納可能
価格
本日の銀行送金レート: 1USD=115.27円で換算しております。

2016年12月31日まで 年末キャンペーン割引: Global Markets Direct社発行レポート
ご注意: ショッピングカートでは適用されませんので、割引価格についてはお問い合わせください

Back to Top
馬脳炎:パイプライン製品の分析 Equine Encephalitis - Pipeline Review, H2 2016
出版日: 2016年10月26日 ページ情報: 英文 51 Pages
概要

馬脳炎とは蚊が媒介する感染症で、ヒトの脳が重度の炎症に侵されるという特徴があります。主な症状として、突然の発熱や悪寒、人体・関節の疼痛などが挙げられます。場合によっては脳炎が重篤化し、頭痛や見当識障害、震戦、てんかん、麻痺状態などにつながります。

当レポートでは、世界各国での馬脳炎治療用のパイプライン製品の開発状況について分析し、製品開発・上市の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要、最新の業界動向などの情報をお届けします。

イントロダクション

  • 調査範囲

馬脳炎の概要

治療薬の開発

  • パイプライン製品の概要
  • パイプライン製品の比較分析

馬脳炎:企業で開発中の治療薬

馬脳炎:大学/機関で研究中の治療薬

馬脳炎:パイプライン製品の概況

  • 臨床段階の製品
  • 初期段階の製品

馬脳炎:企業で開発中の製品

馬脳炎:大学/機関で研究中の製品

馬脳炎の治療薬開発に従事している企業

  • Akshaya Bio Inc.
  • Altravax, Inc.
  • EpiVax, Inc.
  • Integrated BioTherapeutics, Inc.
  • Karyopharm Therapeutics, Inc.
  • Profectus BioSciences, Inc.

馬脳炎:治療薬の評価

  • 単剤製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

馬脳炎:最近のパイプライン動向

馬脳炎:休止中のプロジェクト

馬脳炎:製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC8579IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Equine Encephalitis - Pipeline Review, H2 2016, provides an overview of the Equine Encephalitis (Central Nervous System) pipeline landscape.

Equine encephalitis (EE) is mosquito transmitted disease that can cause severe inflammation of the brain (encephalitis) in humans. Symptoms include the sudden onset of fever, chills, body and joint aches. Infection can develop into severe encephalitis, resulting in headache, disorientation, tremors, seizures and paralysis. Permanent brain damage, coma and death may also occur in some cases. Approximately a third of patients who develop EE die, and many of those who survive have mild to severe brain damage.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Equine Encephalitis - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Equine Encephalitis (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Equine Encephalitis (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Equine Encephalitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Preclinical and Discovery stages are 8 and 3 respectively for Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 1, 2 and 1 molecules, respectively for Equine Encephalitis.

Equine Encephalitis (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Equine Encephalitis (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Equine Encephalitis (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Equine Encephalitis (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Equine Encephalitis (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Equine Encephalitis (Central Nervous System)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Equine Encephalitis (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Equine Encephalitis (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Equine Encephalitis Overview
  • Therapeutics Development
    • Pipeline Products for Equine Encephalitis - Overview
    • Pipeline Products for Equine Encephalitis - Comparative Analysis
  • Equine Encephalitis - Therapeutics under Development by Companies
  • Equine Encephalitis - Therapeutics under Investigation by Universities/Institutes
  • Equine Encephalitis - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
  • Equine Encephalitis - Products under Development by Companies
  • Equine Encephalitis - Products under Investigation by Universities/Institutes
  • Equine Encephalitis - Companies Involved in Therapeutics Development
    • Akshaya Bio Inc.
    • Altravax, Inc.
    • EpiVax, Inc.
    • Integrated BioTherapeutics, Inc.
    • Karyopharm Therapeutics, Inc.
    • Profectus BioSciences, Inc.
  • Equine Encephalitis - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • DEF-201 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • equine encephalitis vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • equine encephalitis vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • equine encephalitis vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • imatinib mesylate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibodies for Equine Encephalitis and Chikungunya - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody for Venezuelan Equine Encephalitis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • nilotinib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TSI-GSD-104 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Vaccine for Western Equine Encephalitis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • venezuelan equine encephalitis vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Venezuelan equine encephalitis vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • venezuelan equine encephalitis vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • verdinexor - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Westrern Equine Encephalitis Virus Vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Equine Encephalitis - Dormant Projects
  • Equine Encephalitis - Product Development Milestones
    • Featured News & Press Releases
      • Dec 09, 2015: Profectus BioSciences Receives $4.6 Million DOD Grant to Develop Vaccine for Western, Eastern, and Venezuelan Equine Encephalitis Viruses
      • Dec 09, 2015: Profectus BioSciences Receives $4.6 Million DOD Grant to Develop Vaccine for Western, Eastern, and Venezuelan Equine Encephalitis Viruses
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Equine Encephalitis, H2 2016
  • Number of Products under Development for Equine Encephalitis - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Equine Encephalitis - Pipeline by Akshaya Bio Inc., H2 2016
  • Equine Encephalitis - Pipeline by Altravax, Inc., H2 2016
  • Equine Encephalitis - Pipeline by EpiVax, Inc., H2 2016
  • Equine Encephalitis - Pipeline by Integrated BioTherapeutics, Inc., H2 2016
  • Equine Encephalitis - Pipeline by Karyopharm Therapeutics, Inc., H2 2016
  • Equine Encephalitis - Pipeline by Profectus BioSciences, Inc., H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Equine Encephalitis - Dormant Projects, H2 2016

List of Figures

  • Number of Products under Development for Equine Encephalitis, H2 2016
  • Number of Products under Development for Equine Encephalitis - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Targets, H2 2016
  • Number of Products by Stage and Targets, H2 2016
  • Number of Products by Mechanism of Actions, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top